Press Releases

Read our latest announcements and updates.

Media Inquiries: media@infobionic.com | 978.674.8304

January 30, 2019

InfoBionic; Cardiac Monitor Disrupts Current Remote Monitoring with “Full Disclosure Beat-to-Beat” Technology

More than 50% of clinically significant cardiac arrhythmias are recorded after the typical 48-hour monitoring period typical for Holter monitors. These legacy monitors rely on the patient to activate the device when they experience symptoms, but nearly 90 percent of patients cannot recognize themselves as being at high risk prior to an actual heart attack.

September 11, 2018

InfoBionic Secures $50 Million in Financing to Support Continued Growth of the MoMe® Kardia System for Cardiac Arrhythmia Detection

InfoBionic has announced the completion of a $50 million financing to support continued commercial expansion of its MoMe® Kardia system for remote, wireless outpatient monitoring and diagnosis of cardiac arrhythmias.

August 28, 2018

InfoBionic has Entered into an Exclusive Distributorship with BIOTRONIK for MoMe® Kardia in the U.S.; Expects Significant Nationwide Growth

InfoBionic has announced that it has entered into an exclusive distributorship to make BIOTRONIK the exclusive distributor of MoMe® Kardia in the U.S.

February 7, 2018

InfoBionic Exceeds Expectations with Soaring Growth Rates for 2017 as the Company Continues to Disrupt the Traditional Remote Cardiac Monitoring Market with Rapid Adoption of Its MoMe® Kardia System

InfoBionic has announced impressive growth rates for 2017, exceeding the company’s projected milestones for the year. The growth was driven by significant market acceptance and adoption of its MoMe® Kardia remote cardiac monitoring system used to diagnose and manage patients that are suspected of having or are experiencing cardiac arrhythmias.

August 22, 2017

InfoBionic Appoints Gene Cattarina to Board of Directors

InfoBionic has announced the appointment of Gene Cattarina to its Board of Directors, who brings over 40 years of experience in numerous senior executive positions at companies in healthcare information systems, products, medical devices, and professional services.

August 8, 2017

InfoBionic Announces Rapid Growth, Strong Adoption of Its Market-Shifting Remote Cardiac Arrhythmia Monitoring System

InfoBionic has announced significant company growth spurred by rapid adoption of its lead product, MoMe® Kardia, within the strategic markets it has been launched.

April 4, 2017

InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

InfoBionic has announced that Stuart Long was named Chief Executive Officer, underscoring the Company’s commitment to widespread market adoption of its transformative wireless remote patient monitoring platform for chronic disease management.

July 27, 2016

Frost & Sullivan Honors InfoBionic for New Product Innovation

Based on its recent analysis of the arrhythmia detection and monitoring market, Frost & Sullivan recognizes InfoBionic with the 2016 North America Frost & Sullivan Award for New Product Innovation. InfoBionic’s MoMe® Kardia system plugs the gaps in traditional cardiac arrhythmia detection devices by optimizing its clinical utility for patients and physicians alike. MoMe Kardia is a wireless remote monitoring system that aids in the detection, management, and diagnosis of cardiac arrhythmias.

July 21, 2016

InfoBionic Successfully Resolves Obsolete Patent Claims

InfoBionic, Inc. has announced that BioTelemetry, Inc. and InfoBionic agreed to dispose of BioTelemetry’s obsolete claims of patent infringement against a first-generation device. InfoBionic is pleased to offer its state-of-the-art, FDA-cleared second-generation MoMe® Kardia System to physicians.

March 16, 2016

InfoBionic Receives FDA 510(k) Clearance for MoMe® Kardia

InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for MoMe® Kardia, a wireless, remote monitoring system designed to aid physicians in their diagnosis of cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring.